The DOI matches its Crossref record; 259 of the 260 references it cites were found in a registry or an index.
Biomarkers in Neurodegenerative Diseases
Abstract
The past decade has seen tremendous efforts in biomarker discovery and validation for neurodegenerative diseases. The source and type of biomarkers has continued to grow for central nervous system diseases, from biofluid-based biomarkers (blood or cerebrospinal fluid (CSF)), to nucleic acids, tissue, and imaging. While DNA remains a predominant biomarker used to identify familial forms of neurodegenerative diseases, various types of RNA have more recently been linked to familial and sporadic forms of neurodegenerative diseases during the past few years. Imaging approaches continue to evolve and are making major contributions to target engagement and early diagnostic biomarkers. Incorporation of biomarkers into drug development and clinical trials for neurodegenerative diseases promises to aid in the development and demonstration of target engagement and drug efficacy for neurologic disorders. This review will focus on recent advancements in developing biomarkers for clinical utility in Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In this study, patients with severe schizophrenia, receiving Cognitive Remediation Therapy (CRT), were differentiated from control participants with less severe schizophrenia (no CRT recommended) by non-verbal speech analysis.”
From A Review of Automated Speech and Language Features for Assessment of Cognitive and Thought Disorders (2020) · cites this paper as [39]
In the citing paper
“Additionally, nonverbal speech cues, e.g. counting the number of interruptions, interjections, natural turns, and response times can also indicate identifying features of irregular speech patterns [39].”
From A Review of Automated Speech and Language Features for Assessment of Cognitive and Thought Disorders (2020) · cites this paper as [39]
In the citing paper
“Automated acoustic metrics can be extracted from non-labeled speech samples [35], [39], [38], [102].”
From A Review of Automated Speech and Language Features for Assessment of Cognitive and Thought Disorders (2020) · cites this paper as [39]
In the citing paper
“Preliminary results from this study with participants with severe schizophrenia (n = 8) and less-severe forms of the disease (n = 7) indicate that these nonverbal cues show approximately 90% accuracy in classifying control participants from those with more severe forms of schizophrenia.”
From A Review of Automated Speech and Language Features for Assessment of Cognitive and Thought Disorders (2020) · cites this paper as [39]
In the citing paper
“Most interestingly, changes in the outward flow of speech may precede measurable language-based changes [39], [42].”
From A Review of Automated Speech and Language Features for Assessment of Cognitive and Thought Disorders (2020) · cites this paper as [39]
Citations
Cites
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J. P., Deng, H.-X., et al. (1993) · Nature · doi:10.1038/362059a0 · Cited by 7,062
Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
Biomarkers Definitions Working Group (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113989 · Cited by 6,771
Parkinson's disease: clinical features and diagnosis
Jankovic, J. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.131045 · Cited by 5,720
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Anderson, N. L., & Anderson, N. G. (2002) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r200007-mcp200 · Cited by 4,414
A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD
Renton, A. E., Majounie, E., Waite, A., Simón-Sánchez, J., Rollinson, S., Gibbs, J. R., Schymick, J. C., Laaksovirta, H., van Swieten, J. C., Myllykangas, L., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.09.010 · Cited by 4,409
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Cited by
Sorted by citations
Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing
Boland, B., Yu, W. H., Corti, O., Mollereau, B., Henriques, A., Bézard, E., Pastores, G., Rubinsztein, D. C., Nixon, R. A., Duchen, M. R., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.109 · Cited by 566
Molecular mechanisms of ischemia and glutamate excitotoxicity
Neves, D., Salazar, I. L., Almeida, R. D., & Silva, R. M. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121814 · Cited by 233
Rastogi, S., Sharma, V., Bharti, P. S., Rani, K., Modi, G. P., Nikolajeff, F. K., & Kumar, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22010440 · Cited by 176
Tauroursodeoxycholic acid: a potential therapeutic tool in neurodegenerative diseases
Khalaf, K., Tornese, P., Cocco, A., & Albanese, A. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00307-z · Cited by 156
Pathak, N., Vimal, S. K., Tandon, I., Agrawal, L., Cao, H., & Bhattacharyya, S. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00800-w · Cited by 152
Metadata
- Authors
- Jeromin, A., & Bowser, R.
- Affiliations
- Barrow Neurological Institute (US)
- Corresponding author
- Bowser, Robert
- ORCID
- Bowser, Robert
- Venue
- Advances in Neurobiology
- Publisher
- Springer International Publishing
- Published
- 2017
- Volume
- 15
- Pages
- 491-528
- ISSN
- 2190-5215 (ISSN-L)
- 2190-5223
- OpenAlex
- W2733688271
- Cited by
- 92
- References
- 260
- Citations by year
- 2026: 3 · 2025: 9 · 2024: 11 · 2023: 20 · 2022: 16 · 2021: 13 · 2020: 5 · 2019: 7 · 2018: 8
- FWCI
- 17.51
- Type
- book chapter
- Language
- en
- Open access
- closed
- Locations
- Advances in neurobiology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Neurological Disorders and Stroke (RC1NS068179, NS068179, NS061867)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- biomarkers, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, cerebrospinal fluid biomarkers, blood biomarkers, RNA biomarkers, DNA biomarkers, neuroimaging biomarkers, familial neurodegenerative disease, drug development, clinical trials, target engagement
- MeSH terms
- Alzheimer Disease, Amyotrophic Lateral Sclerosis, Brain, DNA, Humans, Parkinson Disease, Prognosis, RNA, Biomarkers, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
